Conversely, raloxifene, an FDA-approved second-generation SERM, although estrogenic in its reduction of the severity of postmenopausal osteoporosis, is, broadly speaking, antiestrogenic in the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback